Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
This article was originally published in The Tan Sheet
Executive Summary
Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.
You may also be interested in...
Post Pumps Up Nutrition Activity With Nestle’s PowerBar, Musashi Brands
The cereal giant is bulking up its Active Nutrition Group and targeting annualized revenues of $550 million in the nutrition and weight loss sector. Post also continues diversifying its revenues with the deal.
Post Pumps Up Nutrition Activity With Nestle’s PowerBar, Musashi Brands
The cereal giant is bulking up its Active Nutrition Group and targeting annualized revenues of $550 million in the nutrition and weight loss sector. Post also continues diversifying its revenues with the deal.
“Likely” Merck Consumer Health Sale Could Bring $8 Billion – Analysts
Merck executives shift their position about the potential divestiture of the company’s non-pharma assets, including the consumer health business. J.P. Morgan analysts expect a sale of the consumer unit and say Merck’s brands, including Claritin and Coppertone, could grow globally with a new owner.